Search results
Results From The WOW.Com Content Network
The activity of each statin is dependent on the binding affinity of the compound for the substrate site and the length of time it binds to the site. [5] Type 2 statins have unique fluorophenyl group that causes additional polar interaction between the enzyme and the statins, which results in a tighter binding to the enzyme.
From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years. [ 117 ] and $13 billion a year at its peak, [ 118 ] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years."
The best-selling statin is atorvastatin, also known as Lipitor, which in 2003 became the best-selling pharmaceutical in history. [12] The manufacturer Pfizer reported sales of US$12.4 billion in 2008. [13] Patient compliance with statin usage is problematic despite robust evidence of the benefits. [14] [15]
In the process, metabolites, or byproducts, of the drug are produced, which can linger in our blood, urine (and even in our hair) for long after the initial effects of the drug are felt.
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia).
The near-infrared (NIR) window (also known as optical window or therapeutic window) defines the range of wavelengths from 650 to 1350 nanometre (nm) where light has its maximum depth of penetration in tissue. [1] Within the NIR window, scattering is the most dominant light-tissue interaction, and therefore the propagating light becomes diffused ...
Statins are linked to better health outcomes in older adults over the age of 70 with or without previous cardiovascular disease, a new study finds.
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]